See more : Hangzhou Haoyue Personal Care Co., Ltd (605009.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Canopy Growth Corporation (CGC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Canopy Growth Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Everspring Industry Co., Ltd. (2390.TW) Income Statement Analysis – Financial Results
- XAVi Technologies Corporation (3447.TW) Income Statement Analysis – Financial Results
- TNG Limited (TNG.AX) Income Statement Analysis – Financial Results
- IOU Financial Inc. (IOUFF) Income Statement Analysis – Financial Results
- Enel Américas S.A. (ENIA) Income Statement Analysis – Financial Results
Canopy Growth Corporation (CGC)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.canopygrowth.com
About Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 297.15M | 402.90M | 520.33M | 546.65M | 398.77M | 226.34M | 77.95M | 39.90M | 12.70M | 1.15M | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Cost of Revenue | 216.26M | 507.04M | 713.38M | 479.69M | 430.46M | 137.41M | 3.76M | 2.26M | -6.29M | 731.31K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 80.88M | -104.14M | -193.05M | 66.96M | -31.68M | 88.93M | 74.19M | 37.63M | 18.99M | 414.35K | 0.00 | 4.14K | 0.00 | 4.49K | 549.00 |
| Gross Profit Ratio | 27.22% | -25.85% | -37.10% | 12.25% | -7.95% | 39.29% | 95.18% | 94.33% | 149.51% | 36.17% | 0.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 4.61M | 21.72M | 32.34M | 57.58M | 61.81M | 15.24M | 1.45M | 810.00K | 721.00K | 159.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 99.83M | 487.41M | 520.28M | 666.54M | 624.91M | 451.44M | 92.93M | 25.59M | 11.67M | 6.00M | 739.94K | 68.75K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 76.15M | 243.45M | 239.28M | 194.40M | 242.83M | 154.39M | 38.20M | 12.96M | 5.65M | 1.99M | 191.72K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 175.98M | 487.41M | 520.28M | 666.54M | 867.74M | 605.83M | 131.13M | 38.55M | 17.33M | 7.99M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Other Expenses | 129.01M | -21.72M | -32.34M | -57.58M | 63.62M | 21.51M | 20.49M | -585.00K | 2.26M | -966.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 309.60M | 487.41M | 520.28M | 666.54M | 993.17M | 642.58M | 153.07M | 45.43M | 20.30M | 8.15M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Cost & Expenses | 525.86M | 994.46M | 1.23B | 1.15B | 1.42B | 779.99M | 156.82M | 47.69M | 14.02M | 8.88M | 931.66K | 68.75K | 26.16K | 28.56K | 27.47K |
| Interest Income | 16.24M | 24.28M | 6.60M | 21.37M | 66.33M | 49.31M | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.76K | 4.49K | 549.00 |
| Interest Expense | 105.35M | 126.16M | 103.94M | 8.46M | 6.72M | 18.42M | 784.00K | 66.00K | 140.00K | 65.82K | 1.27K | 0.00 | 4.76K | 4.49K | 0.00 |
| Depreciation & Amortization | 53.18M | 80.03M | 114.42M | 127.12M | 125.01M | 46.92M | 20.49M | 6.06M | 2.26M | 362.90K | 4.19K | 0.00 | -4.76K | -4.49K | 0.00 |
| EBITDA | -312.83M | -2.88B | -121.15M | -1.50B | -1.31B | -631.83M | -29.80M | -692.00K | 938.00K | -6.96M | -925.99K | -64.61K | -26.16K | -24.07K | -26.92K |
| EBITDA Ratio | -105.28% | 434.27% | -44.12% | 31.36% | -340.35% | -213.54% | -118.58% | 17.12% | 20.27% | -618.02% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| Operating Income | -228.71M | 1.67B | -1.08B | 44.30M | -1.67B | -553.65M | -78.88M | -15.22M | -2.75M | -7.74M | -931.66K | -64.61K | -21.39K | -19.58K | -26.92K |
| Operating Income Ratio | -76.97% | 413.30% | -208.08% | 8.10% | -418.53% | -244.61% | -101.19% | -38.14% | -21.65% | -675.34% | 0.00% | -1,559.07% | 0.00% | -436.27% | -4,903.10% |
| Total Other Income/Expenses | -242.64M | -455.64M | 750.94M | -440.51M | 159.91M | -59.71M | 68.53M | 3.81M | -621.00K | -912.37K | -1.27K | 0.00 | 0.00 | 0.00 | 26.92K |
| Income Before Tax | -471.36M | -3.31B | -329.43M | -1.68B | -1.51B | -657.78M | -52.54M | -17.06M | -3.37M | -8.93M | -932.93K | -64.61K | -21.39K | 0.00 | 0.00 |
| Income Before Tax Ratio | -158.63% | -822.61% | -63.31% | -308.05% | -378.43% | -290.61% | -67.41% | -42.76% | -26.54% | -779.58% | 0.00% | -1,559.07% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 12.33M | -4.77M | -8.95M | -13.14M | -121.61M | 12.32M | 1.59M | -401.00K | 126.00K | 1.42M | 2.75K | 0.00 | -4.76K | -4.49K | 26.92K |
| Net Income | -657.27M | -3.31B | -320.49M | -1.67B | -1.39B | -670.09M | -54.13M | -16.61M | -3.50M | -8.93M | -932.93K | -64.61K | -21.39K | -24.07K | -26.92K |
| Net Income Ratio | -221.19% | -821.42% | -61.59% | -305.65% | -347.93% | -296.06% | -69.45% | -41.63% | -27.53% | -779.58% | 0.00% | -1,559.07% | 0.00% | -536.27% | -4,903.10% |
| EPS | -6.47 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| EPS Diluted | -8.79 | -71.37 | -8.19 | -44.96 | -39.86 | -1.99 | -0.31 | -0.14 | -0.05 | -0.30 | -15.77 | -0.06 | -0.02 | -0.02 | -0.08 |
| Weighted Avg Shares Out | 101.63M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
| Weighted Avg Shares Out (Dil) | 74.79M | 46.37M | 39.13M | 37.17M | 34.80M | 337.51M | 177.30M | 118.99M | 77.02M | 29.95M | 59.16K | 1.00M | 1.00M | 1.00M | 320.24K |
Canopy Growth Announces Extension of Proxy Voting Deadline for Upcoming Annual General Meeting
Shareholders now have until September 24, 2024 at 9:00 a.m. (Eastern Time) to submit votes to help ensure a quorum is achieved Your Vote is Important!
Canadian Cannabis Stocks Set to Soar Right Now
The Canadian cannabis market remains a focal point for investors this week, especially with companies expanding into the U.S. market. Recently, the U.S. cannabis industry has shown remarkable growth, with sales projected to reach $45 billion by 2025. This expansion...
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Canopy Growth Urges Shareholders to Cast their Vote for the Upcoming Annual Meeting Today
Shareholders are Encouraged to Vote Well in Advance of the Proxy Deadline on September 20, 2024 at 1:00 p.m. (Eastern time) Company Releases Q&A About Annual Meeting Quorum Your Vote is Important!
Cannabis Stocks Get Boost as Trump Backs Easing Restrictions
Shares of Canopy Growth (CGC), Tilray Brands (TLRY), and other cannabis providers surged in intraday trading Monday after former President Donald Trump signaled his support for reducing restrictions on marijuana use.
Investors Heavily Search Canopy Growth Corporation (CGC): Here is What You Need to Know
Zacks.com users have recently been watching Canopy Growth (CGC) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Trump's Marijuana Support Could Ignite Stock Surge – Are You Positioned To Benefit?
The cannabis market is abuzz following former President Donald Trump's recent comments supporting cannabis legalization in Florida.
Best Canadian Cannabis Stocks to Watch in September
Investors looking to capitalize on the growing cannabis market should watch top Canadian marijuana stocks this week. With the US cannabis industry projected to reach $41 billion by 2025, many Canadian companies are expanding their presence across the border. This...
Cannabis stocks rally as analyst hails pot as an ‘increasingly bipartisan' issue
Alliance Global Partners Aaron Grey sees Donald Trump's weekend statement on cannabis as a step forward.
STORZ & BICKEL Debuts Inaugural "Smokeless September Challenge" to Educate Consumers on the Advantages of Vaporization
Switch to Vaporizing and Try the VENTY TUTTLINGEN, Germany , Aug. 29, 2024 /PRNewswire/ - STORZ & BICKEL GmbH (" STORZ & BICKEL "), a world-leading manufacturer of high-end and medically certified vaporizers and a subsidiary of Canopy Growth Corporation...
Source: https://incomestatements.info
Category: Stock Reports